A Phase 4 interventional study of Tegoprazan and Pantoprazole in Gastroesophageal Reflux Disease, sponsored by Carnot Laboratories. Recruiting at 2 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Carnot Laboratories · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Gastroesophageal Reflux with a site in Mexico — 3 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Mexico.
Among the 14 studies in Gastroesophageal Reflux with a site in Mexico, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 14th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →3 of the 14 studies in Gastroesophageal Reflux with a site in Mexico are open now. Recruiting first, the newest first:
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+ · Healthy volunteers
Coordinación de Investigación en Salud, Mexico · Sites in Mexico
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 83 across the 12 interventional studies, 313 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 7 most frequent:
Carnot Laboratories is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Carnot Laboratories has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Gastroesophageal Reflux with a site in Mexico, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-erosive GERD - Tegoprazan
Drug: Tegoprazan
Non-erosive GERD - Pantoprazole
Drug: Pantoprazole
Erosive GERD - Tegoprazan
Drug: Tegoprazan
Erosive GERD - Pantoprazol
Drug: Pantoprazole
Tegoprazan 50 mg daily for 28 days
Pantoprazole 40 mg daily for 28 days
Proportion of subjects with resolution of the main symptoms of gastroesophageal reflux disease
Carlsson-Dent Questionnaire. These tool consists of 7 multiple-choice questions, using a cut-off point ≥ 4 to be considered positive, which qualitatively assesses symptoms associated with GERD and triggering factors such as diet, posture and medications used.
Time frame: From enrollment to the end of treatment at 4 weeks
Plan to share: No — Only IPD used in the results publication
Started Jul 2024 (actual). Primary completion is estimated for Nov 2025, 16 months after the start.
Of 30 phase 4 interventional studies under Gastroesophageal Reflux, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan
Carnot Laboratories